SEC Form 4 · accession 0001144204-18-014636
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James V Caruso
Officer — President and CEO · Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279704
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 12, 2018 | S | 34,000 | $1.1972 | D | 213,548 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2017 to satisfy tax withholding obligations upon vesting of restricted stock.
- F2The price reported in Column 4 of Line 1 with respect to the 34,000 shares sold on March 12, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.26. The Reporting Person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4.